NASDAQ:PTLA Portola Pharmaceuticals (PTLA) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free PTLA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$18.03▼$18.0350-Day Range$18.03▼$18.0352-Week Range$5.31▼$31.73VolumeN/AAverage Volume3.17 million shsMarket Capitalization$1.42 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Portola Pharmaceuticals alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Portola Pharmaceuticals Stock (NASDAQ:PTLA)Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a dual spleen tyrosine kinase and janus kinases inhibitor in development for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor that has completed Phase II clinical trial for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Millennium Pharmaceuticals, Inc.; SRX Cardio; LLC; Ora; and Astellas Pharma Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.Read More Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 PTLA Stock News HeadlinesApril 15, 2023 | usnews.comPortola MiddleMarch 25, 2023 | sfgate.comFault lines in Portola ValleyApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 23, 2023 | usnews.comPortola-Butler Continuation High SchoolFebruary 18, 2023 | yahoo.comPortola, United States - Weather Forecasts | Maps | News - Yahoo WeatherDecember 31, 2022 | forbes.comEagle PharmaceuticalsNovember 21, 2022 | markets.businessinsider.comBerman Tabacco Announces Class Action Settlement In Securities Litigation Involving Purchasers of Portola Pharmaceuticals, Inc. Common StockOctober 7, 2022 | investing.comPTLA_old Historical DataApril 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.September 29, 2022 | seekingalpha.comKPRX Kiora Pharmaceuticals, Inc.See More Headlines Receive PTLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Portola Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/11/2020Today4/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PTLA CUSIPN/A CIK1269021 Webwww.portola.com Phone650-246-7000FaxN/AEmployees324Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,660,000.00 Net Margins-232.73% Pretax MarginN/A Return on Equity-267.86% Return on Assets-54.66% Debt Debt-to-Equity Ratio4.77 Current Ratio4.87 Quick Ratio4.82 Sales & Book Value Annual Sales$116.64 million Price / Sales12.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.67 per share Price / Book10.80Miscellaneous Outstanding Shares78,484,000Free FloatN/AMarket Cap$1.42 billion OptionableOptionable Beta2.32 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Mardi C. Dier (Age 55)Exec. VP, Chief Bus. Officer & CFO Dr. John T. Curnutte (Age 67)Exec. VP and Head of R&D Mr. J. Scott Garland M.B.A. (Age 50)MBA, Pres & CEO Cara MillerVP of Investor Relations and Corp. CommunicationsMr. John B. Moriarty Jr. (Age 51)Exec. VP, Gen. Counsel & Sec. Key CompetitorsArcus BiosciencesNYSE:RCUSKura OncologyNASDAQ:KURAANI PharmaceuticalsNASDAQ:ANIPMorphicNASDAQ:MORFAkero TherapeuticsNASDAQ:AKROView All Competitors PTLA Stock Analysis - Frequently Asked Questions How were Portola Pharmaceuticals' earnings last quarter? Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) issued its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by $0.14. The biopharmaceutical company had revenue of $26.40 million for the quarter, compared to analysts' expectations of $33.88 million. Portola Pharmaceuticals had a negative trailing twelve-month return on equity of 267.86% and a negative net margin of 232.73%. The company's revenue for the quarter was up 18.9% on a year-over-year basis. During the same period last year, the business earned ($1.02) EPS. What other stocks do shareholders of Portola Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Lexicon Pharmaceuticals (LXRX), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Amarin (AMRN), Exelixis (EXEL), NVIDIA (NVDA), Geron (GERN), ACADIA Pharmaceuticals (ACAD) and Aileron Therapeutics (ALRN). This page (NASDAQ:PTLA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portola Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.